287 related articles for article (PubMed ID: 24824433)
1. AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease.
Alto LT; Chen X; Ruhn KA; Treviño I; Tansey MG
PLoS One; 2014; 9(5):e96544. PubMed ID: 24824433
[TBL] [Abstract][Full Text] [Related]
2. Early TNF-Dependent Regulation of Excitatory and Inhibitory Synapses on Striatal Direct Pathway Medium Spiny Neurons in the YAC128 Mouse Model of Huntington's Disease.
Chambon J; Komal P; Lewitus GM; Kemp GM; Valade S; Adaïdi H; Al Bistami N; Stellwagen D
J Neurosci; 2023 Jan; 43(4):672-680. PubMed ID: 36517241
[TBL] [Abstract][Full Text] [Related]
3. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model.
Wu J; Ryskamp DA; Liang X; Egorova P; Zakharova O; Hung G; Bezprozvanny I
J Neurosci; 2016 Jan; 36(1):125-41. PubMed ID: 26740655
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington's disease.
Ebert AD; Barber AE; Heins BM; Svendsen CN
Exp Neurol; 2010 Jul; 224(1):155-62. PubMed ID: 20227407
[TBL] [Abstract][Full Text] [Related]
6. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model.
Chen X; Wu J; Lvovskaya S; Herndon E; Supnet C; Bezprozvanny I
Mol Neurodegener; 2011 Nov; 6():81. PubMed ID: 22118545
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy by proteasome activator, PA28γ, improves motor coordination and proteasome function in Huntington's disease YAC128 mice.
Jeon J; Kim W; Jang J; Isacson O; Seo H
Neuroscience; 2016 Jun; 324():20-8. PubMed ID: 26944602
[TBL] [Abstract][Full Text] [Related]
8. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.
Tang TS; Chen X; Liu J; Bezprozvanny I
J Neurosci; 2007 Jul; 27(30):7899-910. PubMed ID: 17652581
[TBL] [Abstract][Full Text] [Related]
10. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.
Schmidt ME; Buren C; Mackay JP; Cheung D; Dal Cengio L; Raymond LA; Hayden MR
BMC Biol; 2018 Jun; 16(1):58. PubMed ID: 29945611
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of TRPC1-Dependent Store-Operated Calcium Entry Improves Synaptic Stability and Motor Performance in a Mouse Model of Huntington's Disease.
Wu J; Ryskamp D; Birnbaumer L; Bezprozvanny I
J Huntingtons Dis; 2018; 7(1):35-50. PubMed ID: 29480205
[TBL] [Abstract][Full Text] [Related]
12. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
[TBL] [Abstract][Full Text] [Related]
13. Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.
Keeler AM; Sapp E; Chase K; Sottosanti E; Danielson E; Pfister E; Stoica L; DiFiglia M; Aronin N; Sena-Esteves M
J Huntingtons Dis; 2016 Oct; 5(3):239-248. PubMed ID: 27689620
[TBL] [Abstract][Full Text] [Related]
14. Baclofen, a GABAB receptor agonist, enhances ubiquitin-proteasome system functioning and neuronal survival in Huntington's disease model mice.
Kim W; Seo H
Biochem Biophys Res Commun; 2014 Jan; 443(2):706-11. PubMed ID: 24333873
[TBL] [Abstract][Full Text] [Related]
15. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice.
Xie Y; Hayden MR; Xu B
J Neurosci; 2010 Nov; 30(44):14708-18. PubMed ID: 21048129
[TBL] [Abstract][Full Text] [Related]
16. p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease.
Park KHJ; Franciosi S; Parrant K; Lu G; Leavitt BR
Neuroscience; 2017 Jun; 352():79-87. PubMed ID: 28391013
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of Huntington's disease.
Wu Z; Parry M; Hou XY; Liu MH; Wang H; Cain R; Pei ZF; Chen YC; Guo ZY; Abhijeet S; Chen G
Nat Commun; 2020 Feb; 11(1):1105. PubMed ID: 32107381
[TBL] [Abstract][Full Text] [Related]
18. Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease.
Harms AS; Barnum CJ; Ruhn KA; Varghese S; Treviño I; Blesch A; Tansey MG
Mol Ther; 2011 Jan; 19(1):46-52. PubMed ID: 20959812
[TBL] [Abstract][Full Text] [Related]
19. Synaptic scaling up in medium spiny neurons of aged BACHD mice: A slow-progression model of Huntington's disease.
Rocher AB; Gubellini P; Merienne N; Boussicault L; Petit F; Gipchtein P; Jan C; Hantraye P; Brouillet E; Bonvento G
Neurobiol Dis; 2016 Feb; 86():131-9. PubMed ID: 26626081
[TBL] [Abstract][Full Text] [Related]
20. An automated and quantitative method to evaluate progression of striatal pathology in Huntington's disease transgenic mice.
Liang X; Wu J; Egorova P; Bezprozvanny I
J Huntingtons Dis; 2014; 3(4):343-350. PubMed ID: 25575955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
